ANDA 216067, held by Alkem Labs Ltd. Nifedipine.
As of Nov 16, 2026, ANDA 216067 (Nifedipine), held by Alkem Labs Ltd, was first approved by FDA on Mar 29, 2022, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2022 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
| Oct 6, 2022 | Supplement 2Manufacturing | Approved | None posted |
| Apr 26, 2022 | Supplement 1Manufacturing | Approved | None posted |
| Mar 29, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters